PALTUSOTINE TAB

Clinical Criteria Summary

Adults with acromegaly with inadequate response to surgery (or surgery is contraindicated)
Patients with biochemically uncontrolled acromegaly (IGF-1 ≥1.3× ULN if medically naive/off injected octreotide or lanreotide, or ≥1.1× ULN after washout)
Patients with acromegaly biochemically controlled on injected somatostatin receptor ligands (IGF-1 ≤1.0× ULN)

40 mg once daily; may be titrated to 60 mg once daily after 2 to 4 weeks based on IGF-1 levels
Available as 20 mg and 30 mg tablets
Requires fasting administration (≥6 hours after meal, ≥1 hour before next meal)

Primary efficacy target: IGF-1 normalization (≤1.0× ULN)
Secondary efficacy targets: GH <1.0 ng/mL, change in Acromegaly Symptom Diary (ASD) score, and change in IGF-1 levels
Monitor for gallbladder contractility inhibition, stones, or sludge
Monitor blood glucose due to potential alteration of insulin, glucagon, and GH balance
Monitor for sinus bradycardia or PR interval prolongation
Monitor Vitamin B12 levels with long-term use

Most common adverse events: Diarrhea (33.3%), arthralgia (30.0%), headache (20.4%), abdominal pain (16.7%), nausea (13.3%), bradycardia (7.4%)
Adverse event profile consistent with other somatostatin receptor ligands (primarily mild, transient GI effects)
Lower discontinuation rates compared to oral octreotide
Signal of retinal degeneration in animal studies; human significance uncertain

Indicated for acromegaly in adults with inadequate response/contraindication to surgery
Considered a first-line pharmacologic agent
Appropriate for long-term maintenance in patients already controlled on injectable somatostatin receptor ligands (octreotide LAR or lanreotide)
Clinical trial data shows biochemical control rates similar to first-generation injectable SRLs (56% achieving IGF-1 normalization in treatment-naïve patients; 83% maintaining control when switched from injectables)

Significant cost impact compared to first-line agents (octreotide and lanreotide)
Fasting administration requirement may pose adherence challenges for some patients
Real-world adherence data and long-term efficacy/safety data (particularly regarding tumor size control and durability of response) are needed
Not yet incorporated into current acromegaly treatment guidelines; future updates required for algorithm placement
Drug interactions: Strong/moderate CYP3A4 inducers and PPIs may decrease exposure (dose increase as needed); cyclosporine bioavailability may be decreased (monitor levels)